Why Novanta’s strong quarter matters for shareholders now

Novanta (NOVT) posted quarterly revenue that exceeded analyst expectations and issued EBITDA and revenue guidance above forecasts. Yet the stock has slipped since the report, which hints that investor expectations were already high.

Over the past year, Novanta’s share price has moved sharply higher, with a year-to-date share price return of 30.15% and a 1-year total shareholder return of 22.51%. However, the 9.21% share price decline over 90 days suggests some of that momentum has cooled as investors reassess growth potential and risk after the strong guidance upgrade.

Compare Novanta’s sharp move after this earnings surprise with other precision tech and automation stocks that screen well on quality and fundamentals using our curated 20 high quality undiscovered gems list.

Novanta now trades well below the average analyst price target, even after a strong quarter, while one intrinsic value estimate suggests only a small premium. Is the recent pullback a sign of caution, or a mispriced opportunity on valuation grounds?

Most Popular Narrative: 25.6% Undervalued

At a last close of $144.65 against a narrative fair value of $194.50, Novanta is framed as undervalued, with that gap hinging on execution in robotics and medical devices.

Rapid adoption of robotics and automation in manufacturing and healthcare (including AI-enabled warehouse automation, surgical robotics, and future humanoid robotics) is accelerating demand for Novanta's advanced sensing and precision motion technologies. The company's design wins and multi-year contracts (e.g., $50M warehouse robotics deal, multiple new design wins in physical AI and robotics) position it to grow revenue at above-market rates through 2026 and beyond.

Read the complete narrative..

Want to understand why this narrative supports a much higher value for Novanta? The key lies in how earnings, margins and future multiples are modeled. One set of numbers sits at the center of that $194.50 figure. The full narrative lays out those assumptions step by step.

The widely followed narrative uses a discount rate of 8.98% and assumes faster earnings growth, rising profitability and a reduced future P/E compared with today. It effectively argues that Novanta can grow into a higher earnings base while still being valued on a rich, but lower, earnings multiple than now, which together bridge the gap between $144.65 and $194.50.

Result: Fair Value of $194.50 (UNDERVALUED)

However, you still need to weigh the risk that Novanta’s acquisition driven growth plan, or its exposure to trade disruptions and tariffs, could undermine this upbeat narrative.

Another View: What Novanta’s P/E Says About Risk

The narrative fair value argues Novanta is 25.6% undervalued, yet the current P/E of 88.6x is far higher than the US Electronic industry at 29.9x and an estimated fair ratio of 41.5x. That gap points to meaningful valuation risk if sentiment or growth expectations cool. Which signal do you trust more?

Next Steps

With both upside potential and real concerns in play for Novanta, it makes sense to move quickly, review the underlying data, and weigh both the 2 key rewards and 1 important warning sign.

Looking for more Novanta style investment ideas?

If Novanta has your attention, do not stop here. Use the Simply Wall Street Screener to hunt for other opportunities before the crowd catches on.

• Target resilient companies that still trade at appealing valuations by scanning our 46 high quality undervalued stocks that already filter for quality fundamentals.
• Prioritise steadier ride potential by reviewing the 76 resilient stocks with low risk scores which highlights businesses with more resilient profiles and fewer red flags.
• Spot financially sound stocks that can better handle shocks by using the list of solid balance sheet and fundamentals (50 results) tailored to highlight stronger balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.